Pharmaceutical Industry
Filter News
Found 9,313 articles
-
Middle East and Africa pharma economy to reach US$38.8bn by 2021
8/15/2018
CPhI MEA (Middle East and Africa) launches next month as favourable market conditions are driving increased growth across the Middle East and North Africa (MENA) pharma market – ageing and gentrifying populations, increased healthcare spending, and a modernising supply chain are transforming prospects in the region.
-
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service. -
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
-
In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some ...
-
As federal lawmakers continue to wrangle over legislation to help curb the opioid crisis in the United States, the House of Representatives is showing some division over the costs that some pharmaceutical companies may have to pay for Medicare coverage.
-
In September 2016, the U.S. FDA approved Sarepta Therapeutics’ eteplirsen, now marketed as Exondys 51, for Duchenne muscular dystrophy (DMD). And now, two years later, the European Medicines Agency (EMA) has rejected Sarepta’s application for Exondys 51.
-
Shares of Acadia Pharmaceuticals soared more than 26 percent in trading on Thursday and continue to climb this morning in premarket trading after the U.S. Food and Drug Administration affirmed the safety profile of the company’s lead drug, Nuplazid.
-
Release: AbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cance...
9/21/2018
AbbVie, a research-based global biopharmaceutical company, today announced a donation of $5 million to Family Reach to support the organization’s efforts to alleviate the financial burden of cancer on pediatric patients and families across the United States. -
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
9/21/2018
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
-
Almirall acquires Allergan U.S. medical dermatology portfolio*
9/21/2018
lmirall, S.A.(ALM) announced today the finalization of their acquisition of products from Allergan's Medical Dermatology unit in the United States: Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (flurandrenolide).
-
SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
9/21/2018
SanBio Co., Ltd. hereby announces that it has resolved to enter into an equity and business alliances
-
SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
9/21/2018
SanBio Co., Ltd. has agreed to enter into an equity and business alliances
-
Agenus Closes $15 Million Partial Royalty Monetization With XOMA
9/21/2018
Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation
-
Multiple Surgeon Presentations to Showcase Glaukos Products at 2018 European Society of Cataract and Refractive Surgeons Congress
9/21/2018
Glaukos Corporation announced today that its products will be included in various physician presentations at the 36th Congress of the European Society of Cataract and Refractive Surgeons
-
Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe
9/21/2018
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta
-
CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence
9/21/2018
On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU
-
AbbVie Receives Positive CHMP Opinion for a Novel, Chemotherapy-free Combination of VENCLYXTO® (venetoclax tablets) with Rituximab as a Treatment with a Fixed Duration for Patients with Chronic Lymphocytic Leukemia
9/21/2018
If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
-
St. Jude Children's Research Hospital and Tessa Therapeutics Announce Strategic Collaboration
9/21/2018
The collaboration between St. Jude and Tessa aims to advance cellular immunotherapy treatments for childhood cancer
-
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock
9/21/2018
Viking Therapeutics, Inc. today announced the pricing of its public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share.